David Li
  1. Associate

Mr. Li is an associate in Davis Polk's Corporate Department, practicing in the Capital Markets Group. He advises U.S. and non-U.S. companies and investment banks on capital markets transactions, including initial public offerings, follow-on equity offerings and investment-grade and high-yield debt offerings. His practice ranges across a variety of industries, including biotech and healthcare, technology and transportation. 

Work Highlights

  • Initial public offerings by ADC Therapeutics, Ayala Pharmaceuticals, Chewy, Consonance-HFW Acquisition Corp., Gatos Silver, Northern Genesis Acquisition Corp. II and Tradeweb Markets
  • Follow-on equity offerings by ADC Therapeutics, American Well, Applied Genetic Technologies Corporation, BioNTech, Chewy, InflaRx and PTC Therapeutics
  • At-the-market offerings by BioNTech, InflaRx and PTC Therapeutics
  • Investment-grade and high-yield debt offerings by Export Development Canada, FedEx, Gran Tierra Energy, Ingredion, the Province of Alberta, the Province of Ontario, Snap-on, Valero Energy, Visa and XPO Logistics
  • Convertible debt offerings by Encore Capital and PTC Therapeutics
  • Private placements by Ayala Pharmaceuticals and I-Mab

Professional History

  • Davis Polk since 2018

Practice Focus

Bar Admissions

  • State of New York


  • B.Sc., Psychology, University of Toronto, 2015
  • J.D., Harvard Law School, 2018
    • magna cum laude
    • Senior Editor, Harvard Law Review


  • Mandarin